U.S. FDA Commissioner Hamburg Promotes Regulatory Science Collaboration In China Visit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China is predicted to become the world's second largest economy by the end of this year, and last week, U.S. FDA Commissioner Margaret Hamburg made her first trip to China to boost communication with China's State FDA and to emphasize that the relationship between the U.S. and China has become more important than ever
You may also be interested in...
U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
SAN FRANCISCO - U.S. FDA is gathering information that will likely help the agency intensify its gaze on Indian and Chinese OTC, nutraceutical and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less stringent oversight
U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
SAN FRANCISCO - U.S. FDA is gathering information that will likely help the agency intensify its gaze on Indian and Chinese OTC, nutraceutical and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less stringent oversight
U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
The agency is gathering information to sharpen its risk-assessment approach and determine inspection priorities for nutraceuticals and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less-stringent oversight.